Can BPaL or BPaLM Be Used in CKD with Creatinine 240?
Yes, both BPaL and BPaLM regimens can be used in patients with chronic kidney disease and elevated creatinine, as the component drugs (bedaquiline, pretomanid, linezolid, and moxifloxacin) are predominantly metabolized hepatically and do not require dose adjustment for renal impairment. 1
Renal Safety Profile of BPaL/BPaLM Components
- Bedaquiline, pretomanid, and moxifloxacin are primarily metabolized by the liver and are safe for use in renal impairment without dose adjustment 1
- Linezolid does not require dose adjustment in renal failure, though heightened monitoring for hematologic adverse effects (myelosuppression, anemia) is warranted in CKD patients 1, 2
- The FDA label for pretomanid specifically notes that patients with kidney problems should inform their physician, but does not contraindicate use or require dose modification 3
Regimen Selection Based on Fluoroquinolone Susceptibility
- For fluoroquinolone-susceptible MDR/RR-TB, use the 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) as the preferred treatment 4
- For pre-XDR TB with fluoroquinolone resistance, use the BPaL regimen (bedaquiline, pretomanid, linezolid without moxifloxacin) for 6-9 months 5, 4
- If fluoroquinolone resistance is detected after starting BPaLM, stop moxifloxacin and continue as BPaL 6, 4
Eligibility Criteria for Your Patient
- Patients must not have prior exposure >30 days to bedaquiline, pretomanid, or linezolid 6
- HIV co-infection does not preclude BPaL/BPaLM use 6
- CKD is not listed as a contraindication in WHO guidelines or FDA labeling 5, 3
- The patient must be ≥14 years of age and not pregnant or breastfeeding 6
Critical Monitoring Requirements in CKD Patients
Hematologic Monitoring
- Baseline complete blood count, then weekly monitoring for myelosuppression (anemia, thrombocytopenia, neutropenia) as linezolid toxicity may be increased in CKD 6, 1
- Consider linezolid 600 mg daily for 26 weeks rather than 1200 mg to minimize hematologic toxicity while maintaining efficacy—the ZeNix trial demonstrated 91% favorable outcomes with 600 mg daily for 26 weeks with only 2% myelosuppression versus 22% with 1200 mg 7
Cardiac Monitoring
- Baseline ECG and repeat at 2,12, and 24 weeks minimum to monitor for QTc prolongation from bedaquiline and moxifloxacin 6
- Discontinue if QTcF >500 ms or clinically significant ventricular arrhythmia develops 6
- Check and correct electrolytes (calcium, magnesium, potassium) before and during treatment, as CKD patients are prone to electrolyte abnormalities that exacerbate QTc prolongation 3
Neurologic Monitoring
- Baseline peripheral neuropathy assessment, then monthly monitoring as linezolid causes dose-dependent peripheral and optic neuropathy 6, 7
- The 600 mg daily linezolid dose reduced peripheral neuropathy to 13% versus 38% with 1200 mg daily 7
Hepatic Monitoring
- Baseline and monthly liver function tests (AST, ALT, bilirubin, alkaline phosphatase) as all three drugs can cause hepatotoxicity 6
- Avoid alcohol and other hepatotoxic medications during treatment 3
Common Pitfalls to Avoid
- Do not delay treatment waiting for fluoroquinolone susceptibility testing—start BPaLM empirically and switch to BPaL if resistance is documented 6, 4
- Do not use ethambutol or aminoglycosides (streptomycin, amikacin, kanamycin) in CKD patients as these require dose adjustment and have increased toxicity in renal impairment 5, 8
- Do not assume CKD requires longer treatment regimens—the 6-month BPaLM duration is appropriate if eligibility criteria are met 4
- Do not use BPaL/BPaLM if there is known resistance to any component drug—switch immediately to an 18-month individualized regimen 6